2m 2m 2m 2m 2m 2m 2m
RAPPORT THERA (RAPP)
NASDAQ
$38.50+$3.60 (+10.31%)
Price as of Jun 03, 2026 5:14 PM EDT- $1.9BMarket Cap
- 185.13%1-Year Change
- BiotechnologyIndustry
RAPPORT THERA (RAPP)
$38.50+$3.60 (+10.31%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | 69,000 N/A | |
Gross Profit | 0 +100.00% | -69,000 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -94.8M +55.56% | -60.9M N/A | |
Depreciation and Amortization Expense | 1.0M +21.22% | 839,000 N/A | |
Total Operating Expenses | 125.1M +50.62% | 83.1M N/A | |
Operating Profit | -125.1M +50.62% | -83.1M N/A | |
Interest Income | 13.6M +12.18% | 12.1M N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 13.6M +12.18% | 12.1M N/A | |
Total Nonoperating Income and Expense | 13.6M +186.77% | 4.7M N/A | |
Income before Taxes | -125.1M +59.75% | -78.3M N/A | |
Income Taxes | 0 N/A | 0 N/A | |
Extraordinary Items | 0 N/A | 0 N/A | |
Net Income | -111.5M +42.37% | -78.3M N/A | |
Net Income from Continuing Operations Applicable to Common | -111.5M +42.37% | -78.3M N/A | |
Basic EPS and Net Income | -2.86 -24.34% | -3.78 N/A | |
Diluted EPS and Net Income | -2.86 -24.34% | -3.78 N/A | |
Basic Weighted Average Shares | 38.9M +87.74% | 20.7M N/A | |
Diluted Weighted Average Shares | 38.9M +87.74% | 20.7M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 52.6M -7.32% | 56.8M N/A | |
Short-Term Investments | 437.9M +76.23% | 248.5M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 490.5M +60.68% | 305.3M N/A | |
Total Current Assets | 498.6M +60.93% | 309.8M N/A | |
Accumulated Depreciation | 2.0M +105.39% | 965,000 N/A | |
Property and Plant and Equipment and Net | 3.0M -15.67% | 3.5M N/A | |
Total Long-Term Assets | 985,000 +515.63% | 160,000 N/A | |
Total Assets | 512.4M +62.71% | 314.9M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 19.0M +117.28% | 8.8M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 8.7M +1,081.19% | 739,000 N/A | |
Total Liabilities | 27.8M +192.22% | 9.5M N/A | |
Retained Earnings | -235.2M +90.09% | -123.7M N/A | |
Total Stockholders Equity | 484.7M +58.68% | 305.4M N/A | |
Total Shares Outstanding | 47.8M +30.60% | 36.6M N/A | |
Cash Flow | |||
Cash from Operating Activities | -87.5M +34.93% | -64.8M N/A | |
Capital Expenditures | 616,000 -74.39% | 2.4M N/A | |
Cash from Investing Activities | -187.5M +10.19% | -170.1M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 270.8M +22.18% | 221.6M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | -26.95% N/A | N/A N/A | |
Return on Equity | -28.22% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 26.17 N/A | N/A N/A | |
Cash Ratio | 2.76 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow